1Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritonealpeffusion for the prevention of peritoneal recurrence of gastric cancer. World J Surg ,1994, 18: 150-155.
2Esquivel J, Vidal Jove J, Steves MA, et al. Morbidity and mortality ofcytoreductive surgery and intraperitoneal chemotherapy. Surgery, 1993, 113: 631-636.
3Sugarbaker PH. Rationale for perioperative intraperitoneal chemotherapy as asurgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat, 1988, 1:6-9.
4Sautner T, Hofbauer F, Depisch P, et al. Adjuvant intraperitoneal cisplatinchemotherapy dose not improve long-term survival after surgery for advanced gastriccancer. J Clin Oncol, 1994, 12: 970-974.
5Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperativechemohyperthermia against peritoneal recurrence of serosal invansion positive gastriccancer. World J Surg, 1995, 19:450-454.
6Fujimoto S, Makoto T, Endoh F, et al. Prevention of peritoneal recurrence ingastric cancer by the chemohyperthermia peritoneal perfusion. First International GastricCancer Congress. Kyoto, 1995, 1655-1657.
7Sugarbaker PH, Averbach AM, Jacquet D, et al. A simplified approach to hyperthermicintraoperative intraperitoneal chemotherapy (HIIC)using a self retaining retractor. CancerTreat Res, 1996, 82: 415-421.
